MGC has received a second order of ArtemiCTM worth US$1m from AMC. Pic: via Getty Images.
MGC’s ArtemiC validated by second US$1m order from AMC
Health & Biotech
share
MGC Pharma has received a vote of confidence in ArtemiC after receiving a second order worth US$1m for the over the counter anti-inflammatory and treatment for moderate COVID 19 from AMC Pharma.
AMC’s latest order, which has been secured with an immediate down payment of US$150,000 ($226,395), increases the total orders for ArtemiC (an OTC version of CimetrA®) to over 100,000 units.
ArtemiCTM is a non-cannabis, all-natural medical spray developed by MGC Pharma that has proven to prevent deterioration of COVID-19 patients along with acting as an anti-inflammatory across a wide range of chronic diseases.
MGC Pharmaceuticals (ASX:MXC) noted that the new order comes alongside AMC’s new supply agreement to distribute to over 100 Holistic and Wellness Chiropractic offices in California, and Florida, which is expected to ramp-up sales of ArtemiC through increased distribution across the US.
The treatment was listed by the US Food and Drug Administration as an OTC Unlicensed Drug on the National Drug Code Database in March this year, allowing it to be sold through the US Pharmacy Benefit Management (PBM) networks.
“This order from AMC validates ArtemiC for the US market and demonstrates our ability to supply an FDA authorised product in a world leading market,” managing director Roby Zomer said.
“This order, combined with AMC’s new supply agreement to distribute across the US, gives us confidence for the future growth of MGC.”
Clinically-tested and proven
ArtemiC uses Swiss Pharmacan’s MyCell and GraftBio’s SNEDD technology, which have been proven to increase the bioavailability of the natural ingredients used in its formulation, namely curcumin, boswellia serrata, artemisinin and Vitamin C.
A Phase-2 double-blind, placebo-controlled Clinical Trial on 50 patients with COVID-19, ArtemiC has demonstrated a full safety and efficacy profile with no drug-adverse events whilst proving to be able to prevent deterioration of COVID-19 patients and achieve faster clinical improvement.
Subsequent trials have also proven ArtemiC to be an effective anti-inflammatory across a wide range of chronic diseases.
This article was developed in collaboration with MGC Pharmaceuticals, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
